Research on molecular markers for epigenetic changes in myeloid malignancies.
10.3760/cma.j.issn.1003-9406.2013.06.012
- Author:
Lin LI
1
;
Xue-mei SUN
Author Information
1. Department of Hematology, Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210029, P.R. China. wokibb@gmail.com.
- Publication Type:Journal Article
- MeSH:
Biomarkers, Tumor;
genetics;
metabolism;
Bone Marrow Neoplasms;
etiology;
genetics;
Epigenesis, Genetic;
Humans;
Mutation
- From:
Chinese Journal of Medical Genetics
2013;30(6):687-692
- CountryChina
- Language:Chinese
-
Abstract:
Novel recurrent somatic mutations have been identified in patients with myeloid malignancies including myeloproliferative neoplasms (MPNs), myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML). Mutations of tet methylcytosine dioxygenase 2 (TET2), DNA methyltransferase 3A (DNMT3A), isocitrate dehydrogenase (IDH)1/2, enhancer of zeste homologue 2 (EZH2) and additional sex combs-like 1 (ASXL1) have been shown to play important roles in the regulation of epigenetic patterning, and may be used as molecular predictors for pathogenesis and clinical outcome for patients with myeloid malignancies.
